Agios Pharmaceuticals has been granted a patent for methods of treating pyruvate kinase deficiency, sickle cell disease, or thalassemia using mitapivat. The treatment involves administering specific doses of mitapivat in combination with a secondary drug, such as an inducer of cytochrome P450. GlobalData’s report on Agios Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Agios Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Agios Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Agios Pharmaceuticals's grant share as of January 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of hemolytic anemia with mitapivat and cyp3a4/5 inducer

Source: United States Patent and Trademark Office (USPTO). Credit: Agios Pharmaceuticals Inc

A recently granted patent (Publication Number: US11878049B1) discloses a method for treating hemolytic anemia in a subject by administering varying doses of mitapivat or its pharmaceutically acceptable salt along with a moderate inducer of cytochrome P450 3A4/5 (CYP3A4/5). The method involves administering doses ranging from 10 mg/day to 200 mg/day of mitapivat, with specific dosing regimens outlined in the claims.

The patent claims detail specific dosing regimens for administering mitapivat, ranging from 10 mg/day to 200 mg/day, along with the use of a moderate inducer of CYP3A4/5 for treating hemolytic anemia. The method involves oral administration of mitapivat in tablet form, with additional components like microcrystalline cellulose, mannitol, croscarmellose sodium, and sodium stearyl fumarate included in the tablet composition. The patent provides a structured approach to treating hemolytic anemia, offering specific dosage levels and administration methods for healthcare professionals to follow when utilizing mitapivat for this condition.

To know more about GlobalData’s detailed insights on Agios Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies